Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas’ medical technologies portfolio is headlined by the h-Patch™ technology. The first use of the h-Patch™ technology will be the V-Go™ disposable insulin delivery device for continuous delivery of insulin at a preset basal rate for on-demand bolus dosing around mealtimes.
In addition to V-Go™, Valeritas’ delivery technology portfolio includes the h-Patch™ for the delivery of other compounds beyond insulin, the Mini-Ject™ Pre-Filled Needle-Free Delivery System, and the Micro-Trans™ Microneedle Transdermal Delivery Patch. These technologies, when combined with certain compounds, are designed to provide unique products that allow precise dosing in previously difficult to treat conditions.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 09/01/11 | Series C | 150M | Unknown |